Table 4. Some Examples of Co-encapsulation of Anticancer and PTT Agents in Nanocarriersa.
| co-encapsulated anticancer agents | composition of NC | size (nm) | surface properties | target tissue | status | ref |
|---|---|---|---|---|---|---|
| DOX, gold-coated iron oxide NP | PSMA | 206 | unconjugated | colon cancer | in vitro, in vivo | (166) |
| CPT, PTT | molybdenum oxide hollow nanosphere | 142 | PEG4000ylated | cervical cancer, breast cancer, pancreatic cancer | in vitro, in vivo | (167) |
| artemisinin, Prussian blue | core–shell dual metal–organic framework | 190 | unconjugated | cervical cancer | in vitro, in vivo | (168) |
| DOX, ICG, manganese | polydopamine | 129 | PEG5000ylated | breast cancer | in vitro, in vivo | (169) |
| DOX, PFTTQ | PLL-g-PEG | 80 | PEG2000ylated | breast cancer | in vitro | (170) |
a
Abbreviations: DOX, doxorubicin; ICG, indocyanine green; NP, nanoparticle; PEG, polyethylene glycol; PFTTQ, poly[9,9-bis(4-(2-ethylhexyl)phenyl)fluorene-alt-co-6,7-bis(4-(hexyloxy)phenyl)-4,9-di(thiophen-2-yl)thiadiazolo quinoxaline]; PLL, polylysine; PSMA, poly(styrene-alt-maleic acid).